Tolerability and efficacy study of P2X7 inhibition in experimental Charcot-Marie-Tooth type 1A (CMT1A) neuropathy

by Giovanna Sociali, Davide Visigalli, Thomas Prukop, Ilaria Cervellini, Elena Mannino, Consuelo Venturi, Santina Bruzzone, Michael W. Sereda, Angelo Schenone
Published 2016-11-01

Early short-term PXT3003 combinational therapy delays disease onset in a transgenic rat model of Charcot-Marie-Tooth disease 1A (CMT1A).

by Thomas Prukop, Jan Stenzel, Stephanie Wernick, Theresa Kungl, Magdalena Mroczek, Julia Adam, David Ewers, Serguei Nabirotchkin, Klaus-Armin Nave, Rodolphe Hajj, Daniel Cohen, Michael W Sereda
Published 2019-01-01

Highly Variable Pharmacokinetics of Tyramine in Humans and Polymorphisms in OCT1, CYP2D6, and MAO-A

by Muhammad Rafehi, Frank Faltraco, Johannes Matthaei, Thomas Prukop, Ole Jensen, Aileen Grytzmann, Felix G. Blome, Ralf Günter Berger, Ulrich Krings, Stefan V. Vormfelde, Mladen V. Tzvetkov, Jürgen Brockmöller
Published 2019-10-01

Targeting myelin lipid metabolism as a potential therapeutic strategy in a model of CMT1A neuropathy

by R. Fledrich, T. Abdelaal, L. Rasch, V. Bansal, V. Schütza, B. Brügger, C. Lüchtenborg, T. Prukop, J. Stenzel, R. U. Rahman, D. Hermes, D. Ewers, W. Möbius, T. Ruhwedel, I. Katona, J. Weis, D. Klein, R. Martini, W. Brück, W. C. Müller, S. Bonn, I. Bechmann, K. A. Nave, R. M. Stassart, M. W. Sereda
Published 2018-08-01